|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||24.43|
|Dividend & Yield||1.03 (2.98%)|
|1y Target Est||N/A|
Bioverativ stock popped Wednesday after the Biogen spinoff announced a $400 million acquisition of True North Therapeutics.
Looking for dividend stocks in the gene sequencing field? Check out General Electric, Roche, and Quest Diagnostics.
The biotech giant trades at a wide discount to what we think it's worth.